Pleural mesothelioma

Pleural mesothelioma grows along the tissue covering the lung and inner chest wall. It may cause breathlessness, chest pain, fatigue or recurrent pleural effusion. Asbestos exposure is a major risk factor, often decades before diagnosis, but the absence of a remembered exposure does not exclude the disease.

Sudden or rapidly worsening breathlessness, severe chest pain or fainting warrants urgent assessment. Treatment planning should separate the tumor's extent from reversible contributors to symptoms, such as fluid, infection or a blood clot.

Contrast-enhanced imaging guides a pleural biopsy, often obtained through thoracoscopy or an image-guided core procedure. Fluid cytology can contribute, but a negative result does not reliably exclude mesothelioma, and tissue is often needed to assess invasion and subtype. A specialist should review an uncertain or limited specimen before a major treatment decision.

Epithelioid, sarcomatoid and biphasic mesothelioma have different clinical behavior. Immunostains establish mesothelial lineage and exclude mimics. Loss of BAP1 or MTAP, or CDKN2A homozygous deletion, can support malignancy in the appropriate setting; retained staining does not rule it out. These findings are not, by themselves, a prescription for a targeted drug.

Current ninth-edition TNM assessment includes changes to pleural tumor T descriptors, incorporating quantitative pleural and fissural thickness alongside relevant invasion findings. Reports should identify the edition used; an older stage label cannot simply be copied into a newer treatment discussion. Nodal and distant spread are assessed separately.

CT and, when appropriate for staging, PET-CT assess disease beyond what is visible in one part of the chest. Potential surgical candidates may need further nodal or local assessment. Lung and heart function, kidney function, nutrition and day-to-day activity influence what treatment can be delivered safely.

Three main approaches are platinum plus pemetrexed, nivolumab plus ipilimumab, and pembrolizumab with platinum plus pemetrexed. In the United States, nivolumab–ipilimumab is labeled for first-line adult unresectable malignant pleural mesothelioma; pembrolizumab with chemotherapy is labeled for first-line adult unresectable advanced or metastatic disease. These indications do not require a positive PD-L1 result.

Histology, the need for symptom control, autoimmune disease, an organ transplant, baseline lung inflammation and organ function all affect the choice. Non-epithelioid disease is particularly important in the immunotherapy discussion. A chemotherapy-only approach can remain reasonable when checkpoint treatment is unsuitable.

Pembrolizumab plus chemotherapy improved overall survival over chemotherapy in KEYNOTE-483. That does not establish superiority over nivolumab–ipilimumab, because the two immunotherapy strategies were not compared head to head in that trial. Local labels, funding and delivery arrangements must be checked for the intended country.

MARS 2 randomized patients with resectable pleural mesothelioma to extended pleurectomy/decortication plus chemotherapy or chemotherapy alone. The surgical group had worse survival over the first two years, more serious adverse events and poorer quality of life. This is a substantial reason not to recommend major cytoreduction merely because a scan suggests it is technically possible.

ASCO retains a possible role for highly selected early-stage epithelioid cases after specialist staging and multidisciplinary review. The 2026 Society of Thoracic Surgeons consensus likewise places any chosen resection inside a multimodal plan and favors lung-sparing pleurectomy approaches over extrapleural pneumonectomy. These recommendations do not erase the randomized evidence or guarantee benefit for an individual.

Before surgery, ask what the operation aims to achieve, why this case differs from the MARS 2 population, the team's morbidity and mortality experience, and the nonsurgical alternative. A second mesothelioma-specific opinion is especially useful when recommendations conflict.

Recurrent fluid can be treated alongside anticancer therapy. After assessing whether drainage improves symptoms and whether the lung re-expands, options may include talc pleurodesis or an indwelling pleural catheter. These serve different practical needs; home drainage support and the person's preferences matter.

When the lung cannot adequately re-expand, pleurodesis may not work well because the pleural surfaces cannot meet; a catheter is often the more useful option. Pain control, selected palliative radiation, nutrition and respiratory support should be integrated early. Drainage-related fever, worsening pain or new breathlessness should be reported promptly.

After first-line immunotherapy, platinum–pemetrexed may be considered if it has not already been used and the patient is fit for it. After chemotherapy, checkpoint treatment may be an option for an immunotherapy-naive patient. Progression after chemoimmunotherapy creates a different evidence gap; simply swapping one PD-1 antibody for another is not an established solution.

CONFIRM supported nivolumab versus placebo after platinum treatment in patients not previously treated with checkpoint inhibition. RAMES found a survival signal for gemcitabine–ramucirumab versus gemcitabine in a randomized phase II post-chemotherapy population. Neither study directly establishes the same benefit after modern first-line chemoimmunotherapy, and country-specific access differs.

A tumor's loss of BAP1 staining is not the same as a germline BAP1 pathogenic variant. The ASCO update recommends offering genetic counseling and/or germline testing to patients with pleural mesothelioma, rather than relying only on a young age or obvious family history. Testing should be explained before it is ordered.

A confirmed inherited variant may change screening for other cancers and inform relatives' testing. It does not automatically prove that a PARP inhibitor or another targeted medicine will work. Diagnostic testing, inherited-risk testing and treatment selection are separate questions.

Mesothelin-targeted CAR-T cells have been studied in early human trials, including regional delivery into the pleural space with subsequent checkpoint treatment. These are genetically modified immune cells, distinct from chemotherapy or a standard antibody infusion. Early feasibility and response findings cannot establish routine benefit or be generalized across different cell products.

A useful trial review checks the exact product, phase, tumor target, prior-treatment limits, organ-function criteria, manufacturing time and the center's current enrollment. A publication or hospital name alone does not mean the treatment is available to this patient. Preserve tissue and treatment records early if research participation is being considered.

Track symptoms, activity, weight and fluid-drainage needs alongside imaging. New cough or breathlessness during immunotherapy can reflect progression, infection or immune-mediated pneumonitis; new diarrhea, severe fatigue or endocrine symptoms also need assessment. The next infusion should not be treated as automatic when significant new symptoms appear.

Bring pathology slides and the full report, molecular results, original CT/PET images, any operative or pleural-procedure reports, medicines and responses, and heart, lung and kidney assessments. The review should end with a prioritized plan for cancer control, breathing and pain—not just a longer list of drugs or institutions.